GreenPrints Institutional repository of De La Salle Medical and Health Sciences Institut
Not a member yet
6526 research outputs found
Sort by
Gift of Freedom
No full text1819-RPA-112https://greenprints.dlshsi.edu.ph/collections_3d/1052/thumbnail.jp
Filipino parenting style: a comparative study between generation X and generation Z in the selected towns of Cavite
No full textArtwork 032: Cherubim Spirit Guidance
No full textFor inquiries:
Please call (046) 481-8000 or (02) 8988-3100 local 1525, email us at [email protected], or message us on our Facebook page: https://www.facebook.com/rpamdafscgallery.https://greenprints.dlshsi.edu.ph/painting/1031/thumbnail.jp
Artwork 118: Peaceful Waters
No full textFor inquiries:
Please call (046) 481-8000 or (02) 8988-3100 local 1525,/= / \u3e email us at [email protected],/= / \u3e or message us on our Facebook page: https://www.facebook.com/rpamdafscgallery.https://greenprints.dlshsi.edu.ph/painting/1117/thumbnail.jp
Artwork 082: This Love, It is A Burning Sun
No full textFor inquiries:
Please call (046) 481-8000 or (02) 8988-3100 local 1525, email us at [email protected], or message us on our Facebook page: https://www.facebook.com/rpamdafscgallery.https://greenprints.dlshsi.edu.ph/painting/1081/thumbnail.jp
Artwork 065: Mamalakaya 1
No full textFor inquiries:
Please call (046) 481-8000 or (02) 8988-3100 local 1525, email us at [email protected], or message us on our Facebook page: https://www.facebook.com/rpamdafscgallery.https://greenprints.dlshsi.edu.ph/painting/1064/thumbnail.jp
An economic analysis of BPaL for multidrug-resistant TB in South Africa and the Philippines
No full textBACKGROUND: The WHO endorses bedaquiline, pretomanid, and linezolid (BPaL)-based regimens for multidrug-resistant/rifampicin-resistant TB, and both the Philippines (PH) and South Africa (SA) have adopted these regimens. METHODS: Using a Markov model, we assessed the cost per successful treatment and 5-year budgetary and economic impact of BPaL-based regimens in SA and PH. Treatment outcomes were informed by national electronic registries, SA BPaL Clinical Access Program, and PH operational research. Costs were estimated from the provider perspective. RESULTS: Over 5 years, BPaL-based regimens reduce total costs by 20%–25% in SA and 9%–11% in PH compared with a standard short oral regimen (SSOR) when achieving the same number of successful treatments, due to lower cost per successful treatment from reduced loss to follow-up and mortality. BPaLbased regimens improve treatment success by 22%, leading to more patients completing full treatment and higher overall resource use. Therefore, the budget for BPaL-based regimens is projected to increase by 7%–8% (SA) and 6% (PH) from 2023/24 to 2027/28. CONCLUSION: BPaL-based regimens reduce cost per successful treatment compared with SSOR and require smaller budgets for similar treatment outcomes. Implementation may involve initial budget increases, but improvements in treatment success and long-term health outcomes outweigh these costs, presenting a strong rationale for rollout